Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsight. Endometrial Cancer affects postmenopausal women and is rising due to obesity and aging. DelveInsight’s report covers 55+ pipeline drugs from major companies like Eli Lilly, Karyopharm, and NETRIS. Promising therapies like Selinexor, Abemaciclib, and NP137 are in clinical trials. In June 2025, Daiichi Sankyo started a clinical trial for Enhertu in combination with Keytruda for HER2-expressing endometrial cancer.
The endometrial cancer pipeline report provides insights into the development of new therapies by 50+ companies. Key players like Eli Lilly, Karyopharm, and NETRIS are evaluating drugs like Selinexor and Abemaciclib. In May 2025, Kaida BioPharma entered a manufacturing agreement for KAD101, a biologic for platinum-resistant ovarian cancer with potential in endometrial cancer. PRISM BioLab announced a study with E7386 and Lenvatinib for advanced endometrial cancer at ASCO Congress 2025.
Endometrial cancer, the most common gynecologic cancer in developed countries, is rising due to aging populations and obesity. Risk factors include obesity, metabolic syndrome, diabetes, and genetic factors like Lynch syndrome. Diagnosis involves endometrial biopsy, with transvaginal ultrasound sometimes producing false-negative results. Treatment varies by stage, with newer therapies like immunotherapy showing promise for advanced cases.
Emerging therapies for endometrial cancer include drugs like Selinexor, Abemaciclib, and Envafolimab. Companies like Karyopharm, Eli Lilly, and Alphamab Oncology are developing these drugs in various stages of clinical trials. The report details the mechanism of action, administration route, and phase of development for each drug. Understanding these new therapies is crucial for improving endometrial cancer treatment outcomes.
DelveInsight’s endometrial cancer pipeline report offers a comprehensive analysis of emerging therapies segmented by stage, product type, and mechanism of action. Coverage includes global therapeutic assessment by product type, clinical stages, route of administration, molecule type, and mechanism of action. Key companies like Eli Lilly, Karyopharm, and NETRIS are developing promising drugs like Selinexor and Abemaciclib. Stay informed about the latest advancements in endometrial cancer treatment with this detailed report.
Read more at GlobeNewswire: Endometrial Cancer Clinical Trial Pipeline Insights: 50+